BofA raises Kymera Therapeutics price target to $144
Benzinga/TradingView reports BofA Securities kept Kymera Therapeutics at Buy and raised its price target to $144 from $123.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.